Trials / Not Yet Recruiting
Not Yet RecruitingNCT06346808
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oncolytic virus Plus Anti-PD1 and Chemotherapy | Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ） |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
- First posted
- 2024-04-04
- Last updated
- 2024-04-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06346808. Inclusion in this directory is not an endorsement.